Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
85.95
-0.33 (-0.38%)
At close: Oct 29, 2026, 4:00 PM EDT
85.90
-0.05 (-0.06%)
After-hours: Oct 29, 2026, 4:35 PM EDT
Corcept Therapeutics Employees
Corcept Therapeutics had 730 employees as of December 31, 2025. The number of employees increased by 230 or 46.00% compared to the previous year. That makes Corcept Therapeutics the 17,167th largest employer in the world and 2,385th in the United States.
Employees
730
Change (1Y)
230
Growth (1Y)
46.00%
Revenue / Employee
$1,138,100
Profits / Employee
$74,342
Market Cap
9.29B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 730 | 230 | 46.00% | 730 | 0 |
| Dec 31, 2024 | 500 | 148 | 42.05% | 500 | 0 |
| Dec 31, 2023 | 352 | 53 | 17.73% | 352 | 0 |
| Dec 31, 2022 | 299 | 61 | 25.63% | 299 | 0 |
| Dec 31, 2021 | 238 | 2 | 0.85% | 238 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Caris Life Sciences | 1,846 |
| Twist Bioscience | 979 |
| Madrigal Pharmaceuticals | 915 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Krystal Biotech | 295 |
CORT News
- 2 days ago - Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 3 days ago - Corcept announces results from Part A of Phase 2 BELLA trial of Lifyorli - TheFly
- 3 days ago - Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 9 days ago - 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes - Business Wire
- 14 days ago - Why Healthcare Stocks Are Hot When the AI Trade Runs Cold - Barrons
- 5 weeks ago - Corcept Therapeutics president of endocrinology Sean Maduck to retire - TheFly
- 5 weeks ago - Corcept Announces Planned Leadership Transition - Business Wire
- 5 weeks ago - Corcept announces positive CHMP opinion for Lifyorli - TheFly